[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity

Rhea-AI Filing Summary

ANI Pharmaceuticals (ANIP) reported insider transactions by its SVP – Corp. Dev. & Strategy. On 11/12/2025, the reporting person sold 14,642 shares of common stock at a weighted average price of $89.07, with trades ranging from $89.00 to $89.50. On 11/13/2025, an additional 94 shares were sold at $88.00.

Following these transactions, the filer beneficially owned 73,615 shares directly and 158,490 shares indirectly through Chali Properties LLC, over which the reporting person holds voting and dispositive power.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gassert Chad

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP - CORP. DEV. & STRATEGY

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								73,615	D
Common Stock	11/12/2025		S		14,642	D	$89.07(1)	158,584	I	Held by Chali Properties LLC(2)
Common Stock	11/13/2025		S		94	D	$88	158,490	I	Held by Chali Properties LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold in multiple trades at prices ranging from $89.00 to $89.50. The price reported above reflects the weighted average sales price.

2. The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Remarks:

	/s/ Chad Gassert, by attorney-in-fact Meredith W. Cook	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for ANIP and what is their role?

An officer of ANI Pharmaceuticals with the title SVP – Corp. Dev. & Strategy filed the Form 4.

What shares did the ANIP insider sell on 11/12/2025?

The insider sold 14,642 common shares at a weighted average price of $89.07, with trades from $89.00 to $89.50.

What shares did the ANIP insider sell on 11/13/2025?

The insider sold 94 common shares at a price of $88.00.

How many ANIP shares does the filer own after the transactions?

Beneficial ownership is 73,615 shares directly and 158,490 shares indirectly.

What is Chali Properties LLC’s connection to the ANIP shares?

The 158,490 indirectly owned shares are held by Chali Properties LLC, over which the filer has voting and dispositive power.

Was a weighted average price disclosed for the ANIP share sales?

Yes. For 11/12/2025, the weighted average price was $89.07, with a range of $89.00–$89.50.